Plus Therapeutics present data at the 2024 Congress of Neurological Surgeons, CNS, Annual Meeting September 28 – October 2, in Houston, Texas. Title: Treatment of Recurrent Glioblastoma via Convection Enhanced Delivery with Rhenium Obisbemeda: ReSPECT-GBM Phase 2 Trial Update
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
- Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Plus Therapeutics reports Q2 EPS (71c), consensus (53c)
- Plus Therapeutics presents FORESEE trial results
- Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference